What are parents’ priorities when being invited to enter their child into a clinical trial and how far do they voice their priorities?
© Young et al; licensee BioMed Central Ltd. 2013
Published: 29 November 2013
Research has tended to focus on the information that researchers and ethicists deem important for informed consent to clinical trial participation and on the deficits in patients’ understanding of this information. Drawing on an alternative ‘capabilities’ approach we explored what information parents prioritised when making a decision about their child’s participation in a clinical trial, parents’ comprehension of these issues and how far they voiced their priorities during discussions with recruiters.
Qualitative interview and observational study examining recruitment in four placebo-controlled, double-blind randomised clinical trials of medicines for children. We compared audio-recorded routine parent-recruiter discussions (N=41) about the clinical trials with subsequent semi-structured interviews with parents about their experiences of recruitment.
When making a decision about trial entry, parents’ main priorities were: what clinical benefit the trial might offer their child, their child’s safety; practicalities of participation; research for the common good: access to medication and randomisation. Parents had specific misunderstandings linked to these priorities which had the potential to influence their decisions. While parents had many questions and concerns about trial participation which influenced their decision-making, they rarely voiced these during discussions with recruiters.
Knowing what information patients and carers prioritise when deliberating about entry to a trial can help recruiters when approaching potential participants. Tailoring discussion around these issues and helping patients to voice their particular priorities may enhance recruitment conduct.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.